Showing 7271-7280 of 8826 results for "".
- Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritishttps://practicaldermatology.com/news/deucravacitinib-improves-patient-reported-outcomes-psoriatic-arthritis/2462540/Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study aut
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- Integrated Dermatology Appoints Tushar Ramani, MD, as CEOhttps://practicaldermatology.com/news/integrated-dermatology-appoints-tushar-ramani-md-ceo/2462493/Integrated Dermatology has announced the appointment of Tushar Ramani, MD, as the company's new chief executive officer (CEO). Dr. Ramani will be replacing Jeff Queen, who after two decades as CEO and executive chairman, is transitioning to the role of co-executive chairman of the Board alongside
- American Acne and Rosacea Society (AARS) Releases Response to FDA Citizen's Petition from Valisurehttps://practicaldermatology.com/news/aars-releases-response-to-citizens-petition/2462445/The American Acne and Rosacea Society (AARS) has issued a public response to a recent report from Valisure showing common acne prod
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A
- American Acne and Rosacea Society (AARS) Now Accepting Research Grant Award Applicationshttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-aars-is-now-accepting-applications-for-research-grant-awards/2462440/The American Acne and Rosacea Society (AARS) has announced the commencement of its grant application cycle for AARS Clinical Research Awards ($10K) and the prestigious AARS Research Scholar Award ($75K). According to a press release, the AARS offers its Clinical Research Awards for the a
- New Analysis Provides Evidence-based Recommendations for Vitiligo in Pediatric Patientshttps://practicaldermatology.com/news/evidence-based-recommendations-for-treating-vitiligo-in-pediatric-patients-insights-from-comprehensive-review/2462436/A new consensus statement published in JAMA Dermatology provided evidence-based expert recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients. The authors undertook a rigorous examination of existing literature and expert consensus, aimi
- Analysis of Dermatology Mobile Apps with AI Capability Reveals Weaknesses, Transparency Concernshttps://practicaldermatology.com/news/analysis-of-dermatology-mobile-apps-reveals-weaknesses-transparency-concerns/2462434/A new analysis of dermatology mobile applications (apps) revealed transparency, validation, and accuracy concerns. "With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applicat
- FRONTIER-2: Novel Oral Peptide Maintains Safety, Efficacy Out to 1 Yearhttps://practicaldermatology.com/news/frontier-2-novel-il-23-targting-oral-peptide-maintains-safety-efficacy-out-to-1-year/2462424/A targeted oral peptide targeting interleukin-23 (IL-23) was associated with high rates of clearance and consistent safety through 1 year of treatment in adults with moderate-to-severe plaque psoriasis, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in
- ADORING Trials: Tapinarof Cream, 1% Effective in Patients with Skin of Colorhttps://practicaldermatology.com/news/adoring-trials-tapinarof-effective-in-patients-with-skin-of-color/2462266/In a patient population with diverse skin tones, tapinarof cream, 1% (VTAMA®, Dermavant) was shown to have significant efficacy in both adults and children as young as 2 years of age with atopic dermatitis (AD), according to new results presented at the 2024 American Academy of Dermatology Annual